U.S. markets open in 7 hours 47 minutes
  • S&P Futures

    +4.75 (+0.11%)
  • Dow Futures

    +22.00 (+0.06%)
  • Nasdaq Futures

    +39.00 (+0.29%)
  • Russell 2000 Futures

    +0.50 (+0.02%)
  • Crude Oil

    +0.44 (+0.68%)
  • Gold

    +5.80 (+0.32%)
  • Silver

    +0.12 (+0.45%)

    -0.0001 (-0.01%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.76 (-3.97%)

    +0.0017 (+0.13%)

    -0.0140 (-0.01%)

    -1,252.88 (-2.19%)
  • CMC Crypto 200

    -18.19 (-1.24%)
  • FTSE 100

    +36.87 (+0.52%)
  • Nikkei 225

    +45.27 (+0.15%)

Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
Purple Biotech Ltd.
·8 min read
  • Oops!
    Something went wrong.
    Please try again later.

TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, will be presented in a poster at the American Association of Cancer Research (AACR) 2021 Annual Meeting, taking place in virtual format, on April 10-15 and May 17-21, 2021. These updated data expand on the previously reported results generated from the Company’s collaboration with Professor Ido Wolf, Head of the Oncology Division, Tel Aviv Sourasky Medical Center, and will be highlighted in a presentation titled, “Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2.”

Colorectal cancer (CRC) represents the fourth most frequent cause of brain metastasis, which is the most common brain tumor. However, molecular mechanisms supporting the formation of these lesions from CRC are poorly defined. IRS2 is a known downstream effector of IGF-1 receptors, which regulate cell growth and proliferation. The updated in vitro and in vivo data show the importance of the expression of IRS2 in the development, survival and growth of CRC brain metastasis. Moreover, the increase in trophic effects of IRS2 on brain metastases was associated with increased mitochondrial oxidative phosphorylation. In addition, NT219, an inhibitor of IRS2, and the subject of the Company’s ongoing Phase 1/2 clinical trial for the treatment of multiple cancers, showed in preclinical studies significant and dose-dependent inhibition of CRC cell viability, associated with decreased beta-catenin levels that have been shown to be related to the immune oncology resistance phenotype.

“This important study is the first to demonstrate the significant role of IRS2 in promoting CRC brain metastases and suggests that NT219 could have potential in addressing this critical unmet medical need,” said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. “We continue to be highly encouraged by the compelling mechanism of action data and preclinical results generated to date by NT219. We remain focused on enrolling patients in our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma. We continue to hope to receive top-line data from the first part of this study in the second half of this year.”

Presentation Details:


Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2cancer PDX models


Invasion and Metastasis 1


April 10, 2021



About Purple Biotech
Purple Biotech Ltd. (the “Company”; NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, an FDA-approved fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company’s U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company has recently relocated its corporate headquarters to Rehovot, Israel. For more information, please visit http://www.purple-biotech.com.

Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2019 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov.

Company Contact:
Gil Efron
Deputy CEO & Chief Financial Officer

Investor Relations Contact:
Chuck Padala
+1 646-627-8390